Portal de investigación
Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen.
Autores de INCLIVA
Grupos y Plataformas de I+D+i
Abstract
Aims It is recommended that tumour budding in colon cancer be counted on haematoxylin and eosin-stained sections in a hotspot area of 0.785 mm(2) with a x20 microscope objective. However, tumour buds may be difficult to visualise on haematoxylin and eosin-stained sections, and counting in such a limited area may result in overestimation in cases with focal budding. The aim of this study was to assess the contributions of various factors to improving tumour budding risk stratification: increasing the number of fields counted, using cytokeratin immunostaining, and recording proliferation, the apoptotic index and the emperipoletic index in tumour buds. Methods and results We created an exploratory series composed of 172 cases of colon cancer in all stages, and we analysed the survival probability in a second cohort of 158 stage I-II patients. According to our results, counting of budding in 10 fields was the only factor that was significantly correlated with disease-free survival probability in stage I-II patients [hazard ratio (HR) for high versus low grade of 7.64, 95% confidence interval (CI) 5.54-27.92, P = 0.01; HR for intermediate versus low grade of 3.02, 95% CI 1.54-26.72, P = 0.04). Emperipolesis was frequently observed in tumour buds, whereas the mitotic index and the apoptotic index were extremely low. Although cytokeratin immunostaining increased interobserver concordance, it did not improve the accuracy of tumour budding grading. Conclusions According to our results, counting in 10 fields significantly enhanced the budding grade risk stratification in colon cancer patients, and cytokeratin immunostaining could be reserved as a complementary technique for challenging cases with an inflammatory infiltrate and/or striking fibrosis.
© 2019 John Wiley & Sons Ltd
Datos de la publicación
- ISSN/ISSNe:
- 0309-0167, 1365-2559
- Tipo:
- Article
- Páginas:
- 517-525
- DOI:
- 10.1111/his.13900
- PubMed:
- 31081121
HISTOPATHOLOGY WILEY
Citas Recibidas en Web of Science: 9
Documentos
- No hay documentos
Filiaciones
Keywords
- colon cancer; cytokeratin immunostaining; tumor budding
Financiación
Proyectos y Estudios Clínicos
CONTRATOS RIO HORTEGA
Investigador Principal: NOELIA TARAZONA LLAVERO
CM15/00246 . INSTITUTO SALUD CARLOS III
Enfermedad mínima residual en cánceres colorrectales de alto riesgo resecados. Valor de las biopsias líquidas en el seguimiento y análisis de la heterogeneidad tumoral.
Investigador Principal: ANDRÉS CERVANTES RUIPEREZ
PI15/02180 . INSTITUTO SALUD CARLOS III . 2016
CONTRATOS JUAN RODES
Investigador Principal: DESAMPARADOS RODA PEREZ
2016/197 . INSTITUTO SALUD CARLOS III . 2017
Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en biopsia líquida y modelos de organoides
Investigador Principal: ANDRÉS CERVANTES RUIPEREZ
PI18/01909 . INSTITUTO SALUD CARLOS III . 2019
Cita
Martinez C,Fernandez C,Tarazona N,Rosello S,Huerta M,Roda D,Mongort C,Ferrandez A,Navarro S,Cervantes A. Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen. Histopathology. 2019. 75. (4):p. 517-525. IF:3,626. (1).
Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen. Martinez C, Fernandez C, Tarazona N, Rosello S, Huerta M, Roda D, Mongort C et al. HISTOPATHOLOGY. 2019 enero 01. 75 (4):517-525. DOI:10.1111/his.13900. PMID:31081121.
